Globus Medical, Inc. (NYSE: GMED) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 18.11 | EPS (ttm) | 4.35 | Insider Own | 17.54% | Shs Outstand | 134.86M | Perf Week | 3.01% |
| Market Cap | 10.63B | Forward P/E | 15.32 | EPS next Y | 5.14 | Insider Trans | -0.23% | Shs Float | 133.90M | Perf Month | 3.73% |
| Enterprise Value | 10.18B | PEG | 0.08 | EPS next Q | - | Inst Own | - | Short Float | 5.28% | Perf Quarter | -12.63% |
| Income | 584.43M | P/S | 3.43 | EPS this Y | 10.73% | Inst Trans | - | Short Ratio | 4.02 | Perf Half Y | -12.67% |
| Sales | 3.10B | P/B | 2.25 | EPS next Y | 8.54% | ROA | 10.79% | Short Interest | 7.07M | Perf YTD | -9.76% |
| Book/sh | - | P/C | 13.70 | EPS next 5Y | 12.01% | ROE | 13.04% | 52W High | 104.84 -22.30% | Perf Year | 47.41% |
| Cash/sh | - | P/FCF | 17.70 | EPS past 3/5Y | 28.44% 31.16% | ROIC | 9.72% | 52W Low | 53.55 52.13% | Perf 3Y | 26.57% |
| Dividend Est. | - | EV/EBITDA | 11.57 | Sales past 3/5Y | 42.16% 30.08% | Gross Margin | 67.86% | Volatility | 3.27% 3.57% | Perf 5Y | -5.12% |
| Dividend TTM | - | EV/Sales | 3.28 | EPS Y/Y TTM | 470.67% | Oper. Margin | 17.62% | ATR (14) | 2.85 | Perf 10Y | 203.16% |
| Dividend Ex-Date | - | Quick Ratio | 2.95 | Sales Y/Y TTM | 23.06% | Profit Margin | 18.92% | RSI (14) | 49.84 | Recom | 2.31 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.56 | EPS Q/Q | 64.71% | SMA20 | 0.94% | Beta | 0.94 | Target Price | 98.88 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | 27.09% | SMA50 | -1.16% | Rel Volume | 0.57 | Prev Close | 78.79 |
| Employees | 6,000 | LT Debt/Eq | 0.02 | Earnings | Aug 06 | SMA200 | -6.14% | Avg Volume | 1.86M | Price | 81.46 |
| IPO Date | Aug 03, 2012 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 21.80% 2.63% | Net Debt/EBITDA | -0.51 | Volume | 1,054,232 | Change | 3.39% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Initiated | UBS | Neutral | $82 |
| Jul-16-26 | Reiterated | Truist Securities | Buy | $115 → $100 |
| Jul-13-26 | Reiterated | RBC Capital | Outperform | $100 → $115 |
| Jul-08-26 | Initiated | BMO Capital | Outperform | $94 |
| Jul-08-26 | Reiterated | Stifel Nicolaus | $64 → $80 | |
| Jun-15-26 | Reiterated | Piper Sandler | Overweight | $115 → $100 |
| May-08-26 | Reiterated | Needham | Buy | $112 → $117 |
| May-08-26 | Reiterated | Wells Fargo | Overweight | $78 → $103 |
| Feb-25-26 | Reiterated | Truist Financial | Buy | $105 → $115 |
| Jan-30-26 | Upgrade | Needham | Hold → Buy | $71 → $112 |
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,100 | 2,939 | 2,519 | 1,568 | 1,023 | 958 | 789 | 785 | 713 | |
| Cost of Goods Sold Incl. D&A | 996 | 958 | 1,035 | 548 | 264 | 239 | 217 | 180 | 159 | |
| Gross Profit | 2,105 | 1,981 | 1,484 | 1,020 | 759 | 719 | 572 | 605 | 554 | |
| Selling, General and Administrative Excl. Other | 1,372 | 1,316 | 981 | 643 | 432 | 408 | 355 | 355 | 312 | |
| Research and Development | 189 | 185 | 164 | 124 | 73 | 97 | 85 | 60 | 55 | |
| Other Operating Expense | -2 | 0 | 173 | 120 | 26 | 42 | 20 | 18 | 17 | |
| Operating Income | 547 | 480 | 166 | 133 | 228 | 172 | 111 | 172 | 169 | |
| Interest Expense | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 117 | 130 | -41 | 32 | 15 | 8 | 14 | 18 | 19 | |
| Net Income Before Taxes | 663 | 610 | 121 | 165 | 243 | 180 | 126 | 190 | 189 | |
| Income Taxes | 76 | 72 | 18 | 43 | 53 | 31 | 24 | 35 | 32 | |
| Consolidated Net Income | 587 | 538 | 103 | 123 | 190 | 149 | 102 | 155 | 156 | |
| Net Income From Continuing Operations | 587 | 538 | 103 | 123 | 190 | 149 | 102 | 155 | 156 | |
| Net Income | 587 | 538 | 103 | 123 | 190 | 149 | 102 | 155 | 156 | |
| EPS (Recurring) | 4.35 | 3.98 | 0.76 | 1.09 | 1.89 | 1.48 | 1.04 | 1.57 | 1.60 | |
| EPS (Basic, Before Extraordinaries) | 4.35 | 3.98 | 0.76 | 1.09 | 1.89 | 1.48 | 1.04 | 1.57 | 1.60 | |
| EPS (Diluted) | 4.28 | 3.92 | 0.75 | 1.07 | 1.85 | 1.44 | 1.01 | 1.52 | 1.54 | |
| EBITDA | 879 | 730 | 474 | 347 | 305 | 265 | 178 | 229 | 219 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 19.03 | 22.27 | 110.28 | 49.80 | 40.15 | 50.14 | 64.57 | 38.74 | 28.10 | |
| Price To Sales Ratio | 3.55 | 4.01 | 4.47 | 3.84 | 7.26 | 7.61 | 8.18 | 7.43 | 5.95 | |
| Gross Margin | 67.90 | 67.40 | 58.91 | 65.05 | 74.19 | 75.05 | 72.50 | 77.07 | 77.70 | |
| Operating Margin | 17.65 | 16.33 | 6.59 | 8.48 | 22.29 | 17.95 | 14.07 | 21.91 | 23.70 | |
| Net Margin | 18.94 | 18.31 | 4.09 | 7.84 | 18.57 | 15.55 | 12.93 | 19.75 | 21.88 | |
| Shares Outstanding | 135 | 135 | 136 | 113 | 100 | 101 | 99 | 99 | 98 | |
| Market Capitalization | 10,997 | 11,787 | 11,249 | 6,022 | 7,427 | 7,292 | 6,457 | 5,829 | 4,241 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Davidar David D | Director | Jun 05 '26 | Sale | 80.76 | 25,000 | 2,019,073 | 510,175 | Jun 09 |
| Davidar David D | Director | Jun 05 '26 | Option Exercise | 26.27 | 25,000 | 656,750 | 535,175 | Jun 09 |
| RHOADS ANN D | Director | Jun 04 '26 | Option Exercise | 26.27 | 25,000 | 656,750 | 40,384 | Jun 08 |
| Huller Kelly | EVP, GC, Corporate Secretary | Feb 25 '26 | Sale | 94.50 | 20,000 | 1,890,000 | 0 | Feb 27 |
| Huller Kelly | EVP, GC, Corporate Secretary | Feb 25 '26 | Option Exercise | 43.58 | 20,000 | 871,600 | 20,000 | Feb 27 |
| Huller Kelly | EVP, GC, Corporate Secretary | Feb 12 '26 | Option Exercise | 45.64 | 10,000 | 456,400 | 10,000 | Feb 17 |
| Huller Kelly | EVP, GC, Corporate Secretary | Feb 12 '26 | Sale | 87.67 | 10,000 | 876,700 | 0 | Feb 17 |
| Kline Kyle | Senior Vice President, CFO | Jan 08 '26 | Sale | 101.10 | 3,594 | 363,353 | 0 | Jan 12 |
| Norwalk Leslie V | Director | Jan 08 '26 | Sale | 101.10 | 2,000 | 202,200 | 10,419 | Jan 12 |
| Kline Kyle | Senior Vice President, CFO | Jan 08 '26 | Option Exercise | 51.87 | 3,594 | 186,421 | 3,594 | Jan 12 |
| Norwalk Leslie V | Director | Dec 12 '25 | Sale | 88.85 | 4,000 | 355,400 | 12,419 | Dec 16 |
| Paul David C | Executive Chairman | Dec 08 '25 | Option Exercise | 25.52 | 34,375 | 877,250 | 60,417 | Dec 10 |
| Kline Kyle | Senior Vice President, CFO | Dec 01 '25 | Sale | 90.00 | 18,542 | 1,668,780 | 0 | Dec 03 |
| Kline Kyle | Senior Vice President, CFO | Dec 01 '25 | Option Exercise | 59.86 | 18,542 | 1,109,875 | 18,542 | Dec 03 |
| Huller Kelly | SVP, GC, Corporate Secretary | Nov 25 '25 | Option Exercise | 25.96 | 7,500 | 194,700 | 7,500 | Nov 28 |